used by about 2 million people worldwide -- was driven by recent evidence that the drug's adverse side effects outweighed any potential benefits.
But that wasn't really news.
Though the new study was more comprehensive than past research because it looked at patients over the course of three years, research since November 2000 has suggested that those who take Vioxx face a heart attack risk four to five times greater than those who take older, equally effective arthritis treatments such as ibuprofen and naproxen.
So why is Merck recalling the drug now?